AlphaMadera
IQVIA Holdings Inc. (IQV)
$258.44
-7.73 (-2.81%)Delayed quote.
Price history
Daily close- Start
- $213.88
- Latest close
- $258.44
- Period change
- +20.83%
- Period low
- $156.66
- Period high
- $279.38
Key metrics
- Market cap
- $44.06B
- Volume
- 1.15M
- Average volume
- 1.43M
- 52-week range
- $154.50 – $284.50
- Beta
- 1.17
- Last dividend
- —
- EPS (TTM)
- $8.32
- P/E ratio
- 31.06
- Revenue (TTM)
- $17.31B
- Net income (TTM)
- $1.39B
- Total assets
- $30.47B
- Total debt
- $16.31B
- Cash and equivalents
- $2.25B
Key financials (trailing twelve months).
Company profile
IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Exchange
- NYSE
- CEO
- Ari Bousbib
- Employees
- 94,000
- Headquarters
- Durham, NC, US
- IPO date
- 2013-05-09
- Website
- https://www.iqvia.com
Financial statements
Annual, last 3 fiscal years. Most recent period first. Reported in USD.
| Metric | FY2025Dec 31, 2025 | FY2024Dec 31, 2024 | FY2023Dec 31, 2023 |
|---|---|---|---|
| Revenue | $16.31B | $15.40B | $14.98B |
| Gross profit | $5.43B | $5.38B | $5.24B |
| Operating income | $2.18B | $2.20B | $1.98B |
| EBITDA | $2.94B | $3.45B | $3.26B |
| Net income | $1.36B | $1.37B | $1.36B |
| Diluted EPS | $7.84 | $7.49 | $7.29 |
| Metric | FY2025Dec 31, 2025 | FY2024Dec 31, 2024 | FY2023Dec 31, 2023 |
|---|---|---|---|
| Cash and equivalents | $1.98B | $1.70B | $1.38B |
| Total assets | $29.94B | $26.90B | $26.68B |
| Total liabilities | $23.31B | $20.83B | $20.57B |
| Total debt | $16.17B | $14.16B | $13.90B |
| Shareholders’ equity | $6.50B | $6.07B | $6.11B |
| Metric | FY2025Dec 31, 2025 | FY2024Dec 31, 2024 | FY2023Dec 31, 2023 |
|---|---|---|---|
| Operating cash flow | $2.65B | $2.72B | $2.15B |
| Capital expenditure | -$603.00M | -$602.00M | -$649.00M |
| Free cash flow | $2.05B | $2.11B | $1.50B |
Quarterly, last 6 quarters. Most recent period first. Reported in USD.
| Metric | Q3 2026Sep 30, 2026 | Q2 2026Jun 30, 2026 | Q1 2026Mar 31, 2026 | Q4 2025Dec 31, 2025 | Q3 2025Sep 30, 2025 | Q2 2025Jun 30, 2025 |
|---|---|---|---|---|---|---|
| Revenue | $4.43B | $4.37B | $4.15B | $4.36B | $4.10B | $4.02B |
| Gross profit | $1.50B | $1.44B | $1.35B | $292.00M | $1.37B | $1.32B |
| Operating income | $572.00M | $506.00M | $514.00M | $732.00M | $553.00M | $506.00M |
| EBITDA | $952.00M | $790.00M | $808.00M | $1.05B | $883.00M | $781.00M |
| Net income | $350.00M | $256.00M | $274.00M | $514.00M | $331.00M | $266.00M |
| Diluted EPS | $2.10 | $1.53 | $1.61 | $2.99 | $1.93 | $1.54 |
| Metric | Q3 2026Sep 30, 2026 | Q2 2026Jun 30, 2026 | Q1 2026Mar 31, 2026 | Q4 2025Dec 31, 2025 | Q3 2025Sep 30, 2025 | Q2 2025Jun 30, 2025 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $2.25B | $1.91B | $1.95B | $1.98B | $1.81B | $2.04B |
| Total assets | $30.47B | $29.88B | $29.68B | $29.94B | $28.73B | $28.63B |
| Total liabilities | $23.68B | $23.58B | $23.33B | $23.31B | $22.44B | $22.85B |
| Total debt | $16.31B | $16.24B | $16.07B | $16.17B | $15.19B | $15.70B |
| Shareholders’ equity | $6.66B | $6.17B | $6.22B | $6.50B | $6.16B | $5.78B |
| Metric | Q3 2026Sep 30, 2026 | Q2 2026Jun 30, 2026 | Q1 2026Mar 31, 2026 | Q4 2025Dec 31, 2025 | Q3 2025Sep 30, 2025 | Q2 2025Jun 30, 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | $825.00M | $558.00M | $618.00M | $735.00M | $908.00M | $443.00M |
| Capital expenditure | -$158.00M | -$198.00M | -$127.00M | -$174.00M | $293.00M | -$151.00M |
| Free cash flow | $667.00M | $360.00M | $491.00M | $561.00M | $1.20B | $292.00M |